{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T22:58:18Z","timestamp":1762297098746},"reference-count":44,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2006,5,12]],"date-time":"2006-05-12T00:00:00Z","timestamp":1147392000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2006,6]]},"abstract":"<jats:sec><jats:title>Summary<\/jats:title><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To investigate the efficacy and safety of renzapride, a potent 5\u2010hydroxytryptamine type\u20104 receptor full agonist and 5\u2010hydroxytryptamine type\u20103 receptor antagonist in patients with constipation\u2010predominant irritable bowel syndrome.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this dose\u2010escalating pilot study, 17 patients with constipation\u2010predominant irritable bowel syndrome received placebo, renzapride 2\u2003mg o.d. and renzapride 2\u2003mg b.d. sequentially for 28\u2003days. Response was determined by radio\u2010opaque marker measurement of overall gastrointestinal and segmental colonic transit and patients\u2019 assessment of their irritable bowel syndrome symptoms.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Renzapride reduced mean overall gastrointestinal transit time (placebo, 2.9\u2003\u00b1\u20031.6\u2003days; renzapride 2\u2003mg o.d., 2.6\u2003\u00b1\u20031.4\u2003days; renzapride 2\u2003mg b.d., 1.9\u2003\u00b1\u20031.6\u2003days) (<jats:italic>P<\/jats:italic>\u2003=\u20030.024) and accelerated segmental colonic transit, with statistically significant differences for renzapride 2\u2003mg b.d. over placebo in caecum\/ascending colon (<jats:italic>P<\/jats:italic>\u2003=\u20030.019) and descending colon (<jats:italic>P<\/jats:italic>\u2003=\u20030.022). Renzapride also reduced abdominal pain, increased the number of pain\u2010free days and improved stool consistency. The frequency of reported adverse events was similar on renzapride and placebo.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Renzapride is well\u2010tolerated, stimulates gastrointestinal transit and improves symptoms in patients with constipation\u2010predominant irritable bowel syndrome, particularly at the 2 mg b.d. dose, where improvements in gastrointestinal symptoms were evident over placebo. This study has established proof of concept and supports further investigation of renzapride in patients with constipation\u2010predominant irritable bowel syndrome.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1365-2036.2006.02940.x","type":"journal-article","created":{"date-parts":[[2006,5,12]],"date-time":"2006-05-12T15:44:58Z","timestamp":1147448698000},"page":"1655-1665","source":"Crossref","is-referenced-by-count":37,"title":["Pilot study of the efficacy of renzapride on gastrointestinal motility and symptoms in patients with constipation\u2010predominant irritable bowel syndrome"],"prefix":"10.1111","volume":"23","author":[{"given":"J.","family":"TACK","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. J.","family":"MIDDLETON","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. C.","family":"HORNE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"PIESSEVAUX","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. S.","family":"BLOOR","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N. L.","family":"MEYERS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. M. J.","family":"PALMER","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,5,12]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8553(05)70362-9"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(90)91023-Y"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(91)90717-Y"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01303162"},{"key":"e_1_2_6_6_2","first-page":"451","article-title":"Irritable bowel syndrome","volume":"88","author":"Farthing MJG","year":"1995","journal-title":"Q J Med"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01456.x"},{"key":"e_1_2_6_8_2","first-page":"75","article-title":"Functional bowel disorders and functional abdominal pain","volume":"5","author":"Thompson WG","year":"1992","journal-title":"Gastroenterol Int"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-116-12-1001"},{"key":"e_1_2_6_10_2","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/0016-5085(93)90293-L","article-title":"What are functional bowel disorders","volume":"105","author":"Zighelboim J","year":"1993","journal-title":"Gastroenterology"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199312233292608"},{"key":"e_1_2_6_12_2","first-page":"557","article-title":"Learned illness behaviour in patients with irritable bowel syndrome and peptic ulcer","volume":"295","author":"Whitehead WE","year":"1982","journal-title":"Dig Dis Sci"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.45.2008.ii25"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-116-12-1009"},{"key":"e_1_2_6_15_2","first-page":"S252","article-title":"The role of serotonin in the pathophysiology of irritable bowel syndrome","volume":"7","author":"Crowell MD","year":"2001","journal-title":"Am J Manag Care"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199856010-00002"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1999.00002.x-i2"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01536922"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1999.00610.x"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1998.00375.x"},{"issue":"2","key":"e_1_2_6_21_2","first-page":"C42","article-title":"Visceral sensitivity and functional bowel disorders: physiopathological role and therapeutic perspectives","volume":"25","author":"Delvaux M","year":"2001","journal-title":"Gastroenterol Clin Biol"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2982.2003.00389.x"},{"key":"e_1_2_6_23_2","first-page":"CD003960","article-title":"Tegaserod for the treatment of irritable bowel syndrome","author":"Evans BW","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.5.11.2369"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2001.01094.x"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199958030-00013"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(89)90304-X"},{"key":"e_1_2_6_28_2","first-page":"631","article-title":"Gastrointestinal prokinetic benzamides: The pharmacology underlying stimulation of motility","volume":"47","author":"Briejer MR","year":"1995","journal-title":"Pharmacol Rev"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-3565(04)00391-X"},{"key":"e_1_2_6_30_2","first-page":"SVI","article-title":"Efficacy and safety of renzapride in patients with constipation\u2010predominant IBS: a phase IIb study in the UK primary healthcare setting","volume":"52","author":"George A","year":"2003","journal-title":"Gut"},{"key":"e_1_2_6_31_2","first-page":"SIII","article-title":"Effects of single oral doses of renzapride on gastrointestinal motility in fasted, healthy subjects","volume":"51","author":"Meyers NL","year":"2002","journal-title":"Gut"},{"key":"e_1_2_6_32_2","first-page":"SIII","article-title":"Efficacy and safety of renzapride in patients with constipation\u2010predominant irritable bowel syndrome","volume":"51","author":"Meyers NL","year":"2002","journal-title":"Gut"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/0166-2236(88)90011-2"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00265977"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1987.tb00629.x"},{"key":"e_1_2_6_36_2","volume-title":"Letter \u2013 Propulsid Tablets and Suspension (Cisapride)","author":"Ghevens J"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.321.7256.259"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1999.00655.x"},{"key":"e_1_2_6_39_2","first-page":"256","article-title":"Cardiac toxicity with cisapride","volume":"22","author":"Farrington E","year":"1996","journal-title":"Pediatr Nurs"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.6138.653"},{"key":"e_1_2_6_41_2","first-page":"75","article-title":"Functional bowel disease and functional abdominal pain","volume":"5","author":"Thomson WG","year":"1992","journal-title":"Gastroenterol Int"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365528809095938"},{"key":"e_1_2_6_43_2","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1365-2036.1991.tb00014.x","article-title":"The effects of renzapride, a novel prokinetic agent, in diabetic gastroparesis","volume":"2","author":"Mackie AD","year":"1991","journal-title":"Aliment Pharmacol Ther"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.52.5.671"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1331\/154434504322713228"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2006.02940.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2006.02940.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,4]],"date-time":"2024-02-04T11:17:03Z","timestamp":1707045423000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2006.02940.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5,12]]},"references-count":44,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["10.1111\/j.1365-2036.2006.02940.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2006.02940.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,5,12]]}}}